Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer

@inproceedings{Harshman2015StatinUA,
  title={Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer},
  author={Lauren C Harshman and Mari Nakabayashi and Wanling Xie and Loana Valença and Yongjiang Yu and AaronM. Kantoff and Christopher J. Sweeney and Lorelei A. Mucci and Mark M Pomerantz and Gwo-ShuMary Lee and Philip W. Kantoff},
  year={2015}
}
IMPORTANCE Statin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for SLCO2B1, an organic anionic transporter. We previously demonstrated that genetic variants of SLCO2B1 correlated with time to progression (TTP) during receipt of androgen deprivation therapy (ADT). Statins also use SLCO2B1 to enter cells, and thus we hypothesized that they may compete with DHEAS uptake by the tumor cells.